- Home
- MXCT
MXCT
MaxCyte Inc.
as 04-22-2025 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 275.7M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 621.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $5.26 | Next Earning Date: | 05-07-2025 |
| Revenue: | $38,627,000 | Revenue Growth: | -6.45% |
| Revenue Growth (this year): | 9.05% | Revenue Growth (next year): | 19.98% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandoval David I. | MXCT | GENERAL COUNSEL | Mar 18 '25 | Sell | $3.18 | 353 | $1,122.29 | 64,219 | |
| Swirsky Douglas J | MXCT | CHIEF FINANCIAL OFFICER | Mar 18 '25 | Sell | $3.18 | 6,939 | $22,061.16 | 111,811 | |
| Soleymannezhad Ali | MXCT | Chief Commercial Officer | Mar 18 '25 | Sell | $3.18 | 1,211 | $3,850.13 | 59,439 | |
| Johnston John Joseph | MXCT | Director | Jan 27 '25 | Sell | $4.65 | 3,000 | $13,935.00 | 141,950 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
Zacks
14 days ago
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
Simply Wall St.
14 days ago
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns
Zacks
15 days ago
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
Zacks
18 days ago
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
GuruFocus.com
a month ago
MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
GlobeNewswire
a month ago
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
MT Newswires
2 months ago
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.